OpenPV Signal Explorer
FAERS disproportionality dashboard
Reaction

Endodontic Procedure reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,510 reports · 44 co-occurring drugs

As of the last recalculation, Endodontic Procedure appears in 2,510 FAERS reports alongside 44 co-occurring drug terms. The strongest observed disproportionality signal is ALENDRONATE SODIUM (PRR 20.1).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
DrugCo-reportsPRRROR
Alendronate Sodium22420.120.2
Risedronate Sodium6016.416.4
Anakinra3015.215.2
Denosumab30814.214.3
Calcium, Magnesium, Potassium, And Sodium Oxybates1413.613.6
Diphenhydramine Hydrochloride Capsule, Liquid Filled3212.612.6
Infliximab-Dyyb3510.110.1
Methylprednisolone Acetate99.39.4
Sodium Oxybate698.98.9
Ascorbic Acid248.68.6
Sotalol Hydrochloride168.08.0
Romosozumab-Aqqg127.47.4
Vitamin E277.27.2
Zoledronic Acid347.17.1
Clindamycin236.86.8
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, And Amphetamine Sulfate266.26.2
Hydroxychloroquine Sulfate646.06.0
Armodafinil155.95.9
Raloxifene Hydrochloride105.75.7
Niraparib155.65.6
Belimumab215.55.5
Leflunomide655.35.3
Dextroamphetamine Sulfate, Dextroamphetamine Saccharate, Amphetamine Sulfate And Amphetamine Aspartate265.25.2
Timolol Maleate65.05.0
Buprenorphine Hydrochloride, Naloxone Hydrochloride144.84.8
Risankizumab-Rzaa394.04.0
Etanercept2553.83.8
Teriparatide513.83.8
Upadacitinib343.53.5
Relugolix93.23.2
Bimekizumab83.13.1
Certolizumab Pegol402.92.9
Rucaparib32.82.8
Avapritinib42.72.7
Naltrexone102.72.7
Cariprazine32.72.7
Natalizumab572.62.6
Teriflunomide142.62.6
Conjugated Estrogens And Medroxyprogesterone Acetate72.52.5
Palbociclib252.22.2
Abaloparatide61.71.7
Valbenazine51.61.6
Sarilumab51.61.6
Guselkumab51.21.2

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.